EGFR and glioblastoma: In light of the well‐established oncogenic role of EGFRvIII and the EGFR C‐terminal domain deletion mutant in glioblastoma (GBM) [2, 31, 37, 38], we sought to assess whether MIG6 possesses the capability to inhibit the enzymatic activity of these EGFR mutants and mitigate their oncogenic potential.